Professional
Added to YB: 2024-04-26
Pitch date: 2024-03-31
ACLX [bullish]
Arcellx, Inc.
-4.13%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
Market Cap
$5.2B
Pitch Price
$69.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
-20.91
P/E
-22.87
EV/Sales
130.33
Sector
Biotechnology
Category
growth
Show full summary:
Baron Health Care Fund Added On Position: Arcellx, Inc.
ACLX: Arcellx early-stage biotech developing potentially superior cell therapies for multiple myeloma. Platform may offer safety & scalability advantages vs competitors while matching/exceeding efficacy. Bullish on multiple myeloma space overall, see cell therapy revolutionizing care.
Read full article (1 min)